Science 37 and Signant Health (Signant) have announced a partnership to strengthen capabilities for decentralized or virtual central nervous system (CNS) clinical research.
This collaboration brings together Science 37’s decentralized trial capability and Signant’s data collection technologies, offering sponsors and sites digitally enabled solutions for conducting CNS studies. The combined capabilities span Science 37’s network of patients, telemedicine investigators, central raters, mobile nurses, and technology platform to orchestrate decentralized clinical trials, as well as Signant’s electronic clinical outcomes assessment (eCOA) software, rater training, randomized and trial supply management (RTSM) technology, and are supported by Signant’s long-standing scientific expertise in the CNS space.
The result is a CNS-specific technology and services platform that enables sponsors and sites to offer patients more convenience and choice across various clinical trial models, including virtual and hybrid.
“At Science 37, we strive to bring clinical trials to patients where they live—eliminating the burdens of a traditional site model and increasing patient’s access to clinical research,” said David Coman, CEO of Science 37. “By partnering with Signant Health, we enhance that offering with proven CNS expertise to operationalize and make virtual trials the new reality.”
For more information, click here.